MyRocky vs Hims Canada (2026): GLP-1 Weight Loss Service Comparison

The direct-to-consumer health space in Canada is increasingly contested by two distinct archetypes: homegrown platforms that were built to Canadian regulatory specifications from the outset, and US-founded companies that have expanded northward with adapted versions of their American product. MyRocky and Hims Canada represent both sides of that divide.

Hims was founded in San Francisco and built a sizable US customer base on accessible, DTC-priced prescriptions for hair loss, erectile dysfunction, skincare, and later weight management. Its Canadian entry brought name recognition, significant marketing budgets, and a polished consumer experience. MyRocky was conceived in Mississauga, Ontario, specifically to serve Canadian patients seeking GLP-1 medications - its entire infrastructure, clinical team, and pharmacy are domestically centred.

Both platforms now compete for the same Canadian patient seeking a GLP-1 prescription online. The differences in pricing transparency, province availability, clinical structure, and pharmacy relationships are meaningful enough to warrant a careful comparison before committing to either.

Platform Overview

Canadian-Built vs US-Origin Platform

The origin of a platform shapes more than its branding - it determines the structural decisions made early in product development. MyRocky was designed within the Canadian telehealth regulatory framework, with a dedicated Health Canada-compliant pharmacy in Ontario and a clinical team hired and trained for the Canadian GLP-1 market. The result is a product that does not need to be adapted from US norms: the dosing protocols, the formulary, and the patient intake forms all reflect Canadian clinical practice.

Hims built its Canada offering by adapting its US platform - a process that is common and not inherently problematic, but does create gaps. The most visible gap is province coverage: Hims currently excludes Quebec and New Brunswick from its GLP-1 service, which represents a meaningful portion of the Canadian population. MyRocky serves all ten provinces including Quebec, where distinct regulatory and language requirements make entry more operationally complex.

Hims also lacks a proprietary Canadian pharmacy. Its prescriptions are fulfilled through partner pharmacies, which means delivery timelines, stock availability, and pricing are partially outside the platform's control. For patients who value a single accountable provider from consultation through dispensing, this introduces a coordination layer that does not exist with MyRocky's vertically integrated model.

Where Hims has a genuine advantage is brand familiarity and product breadth. Patients who are already using Hims for another condition - hair loss treatment, for instance - may find it convenient to add weight management within an existing account. And Hims's DTC marketing and clinical communication materials are polished, backed by a US operation that has invested heavily in patient acquisition and retention.

Pricing Breakdown

Pricing transparency is one area where the two platforms differ substantially. MyRocky publishes a straightforward cost structure: $99 for the initial consultation and clinical intake, followed by a program that bundles ongoing clinical support and medication. Hims operates on a post-intake pricing model - you complete the online assessment, and pricing is presented based on the outcome of that assessment. This approach is common in DTC health, but it makes pre-commitment comparison difficult and can lead to sticker shock for patients who assumed DTC health would be low cost.

At lower doses, the two platforms are broadly price-competitive on a monthly basis. The gap tends to widen at higher therapeutic doses, where Hims's per-unit medication costs can push the monthly total above MyRocky's bundled equivalent. The lack of upfront price visibility on Hims makes exact comparison difficult without completing the intake process - which is itself a cost in time and privacy.

Province Coverage

Province coverage is one of the clearest differentiators in this comparison. MyRocky serves all ten provinces; Hims serves eight, excluding Quebec and New Brunswick. The practical implication is straightforward: if you live in Quebec or New Brunswick, MyRocky is the only option between these two platforms.

Clinical Oversight

Both platforms provide access to Canadian-licensed practitioners for GLP-1 assessment and prescribing. The structural difference lies in how those practitioners are organised around the treatment program. MyRocky's clinical team focuses exclusively on GLP-1 weight management and follows a defined titration protocol at four-week intervals. Hims's practitioners are covering a broader range of conditions across its product categories, which can dilute the depth of weight management expertise at any given touchpoint.

MyRocky also includes baseline lab review in its intake process, which supports more informed prescribing decisions and establishes a clinical baseline for monitoring progress. Hims's intake is primarily questionnaire-based, which is standard for telehealth platforms but means less objective clinical data is available to the prescribing practitioner at the outset.

In terms of ongoing monitoring, both platforms offer touchpoints during treatment. MyRocky's cadence is structured and automatically scheduled; Hims provides check-ins within its subscription model though the exact frequency and format vary. For patients who value proactive oversight rather than reactive support, MyRocky's approach is more consistent.

Pharmacy and Dispensing

MyRocky operates its own LegitScript-certified pharmacy in Mississauga. That certification is meaningful: LegitScript verifies that a pharmacy operates in accordance with Canadian law, prescribes only legitimate medications, and employs qualified pharmacists. The in-house pharmacy means that when a prescribing decision is made, the dispensing step is handled within the same organisation - no transfer to a third party, no risk of communication gaps between prescriber and pharmacist.

Hims Canada routes prescriptions to partner Canadian pharmacies. These pharmacies are licensed and legitimate, but the relationship between the Hims clinical team and the dispensing pharmacy is less tightly integrated. Patients who need a dose adjustment or have a question about their medication may find themselves navigating a handoff between the telehealth platform and the pharmacy rather than dealing with a single accountable entity.

Delivery timelines are broadly similar - both platforms can typically fulfil an initial prescription within two to five business days. Refill predictability may favour MyRocky, where the titration schedule makes refill timing foreseeable well in advance.

Pros and Cons

Verdict

For Canadians in Quebec or New Brunswick, the choice is already made: MyRocky is the only option between these two platforms. For the eight provinces where both operate, the decision hinges on what you prioritise.

If you are a new GLP-1 patient who wants a transparent, Canadian-built program with integrated pharmacy and structured clinical oversight, MyRocky is the more coherent choice. The upfront pricing, domestic infrastructure, and specialised clinical focus remove several categories of friction that can derail early-stage GLP-1 treatment.

Hims Canada suits a specific patient type: someone already engaged with the Hims platform for another condition, who wants the convenience of adding weight management without creating a new provider relationship. The product quality is solid and the clinical protocols are sound; the gap with MyRocky is primarily in provincial coverage, pharmacy integration, and pricing transparency - three factors that matter more to some patients than others.

For a first-time GLP-1 patient evaluating these two options side by side, MyRocky's structural advantages - all-province coverage, in-house pharmacy, transparent pricing, and a specialist clinical team - represent a more complete Canadian program.

Sponsored link above. WeightLossInjections.ca may earn a commission if you purchase through this link at no additional cost to you. Editorial content is independent. GLP-1 medications require a valid prescription from a licensed Canadian physician.